George Kollias is Member of the Academy of Athens (http://www.academyofathens.gr/), Professor of Experimental Physiology at the Medical School of the University of Athens, and President and Scientific Director at the Biomedical Sciences Research Center "Alexander Fleming" (http://www.fleming.gr/). He completed his Ph.D. in Molecular Biology at the National and Kapodistrian University of Athens, Greece and his postdoctoral training at the National Institute for Medical Research, Laboratory of Gene Structure and Expression, Mill Hill, London, UK. Prof. Kollias is renowned for proof of principle preclinical studies that led to the development of anti-TNF therapies for rheumatoid arthritis and has pioneered genetic approaches to advance knowledge on the molecular and cellular mechanisms driving chronic inflammation and autoimmunity. Prof. Kollias coordinates the National Research Infrastructure Infrafrontier.GR/Phenotypos (http://www.infrafrontier.gr/) (http://www.precisionmedicine.gr/ from BSRC Fleming, and participates in pMedGR (http://www.precisionmedicine.gr/) from the Medical School of Athens. In 2006 he founded the first CRO-biotech spin-off of BSRC Fleming, Biomedcode Hellas SA (http://www.biomedcode.com/). In 2014, he was awarded the Carol-Nachman Award (https://www.wiesbaden.de/leben-in-wiesbaden/stadtportrait/ehrenbuerger/content/carol-nachman-preis.php) for Rheumatology and in 2015 he received the first Galien Scientific Research Award (http://www.prixgalien.com/en/) at the Prix Galien Greece. Prof. Kollias is Director of the Graduate Program in "Molecular Biomedicine" (http://www.molecularbiomedicine.gr/) at the Medical School of the University of Athens.